AC Immune (ACIU) Amortizatization of Intangibles (2019 - 2025)
AC Immune (ACIU) reported Amortizatization of Intangibles of $407881.4 for Q4 2025, up 110.18% year-over-year from $194058.7 in Q4 2024, and up 19.52% on a QoQ basis from $341279.9 in Q3 2025.
AC Immune (ACIU) has 7 years of Amortizatization of Intangibles data on file, last reported at $407881.4 in Q4 2025.
- Quarterly Amortizatization of Intangibles rose 110.18% year-over-year to $407881.4 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (up 74.43% YoY) and the FY2025 annual result came in at $1.3 million, up 73.24% from the prior year.
- Amortizatization of Intangibles rose to $407881.4 in Q4 2025 per ACIU's latest filing, from $341279.9 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $407881.4 in Q4 2025 and bottomed at $118348.3 in Q1 2021.
- The 5-year median for Amortizatization of Intangibles is $154656.3 (2021), against an average of $195683.2.
- The widest annual swing landed in 2022, when Amortizatization of Intangibles retreated 5.6%; it then soared 110.18% in 2025.
- Tracing ACIU's Amortizatization of Intangibles over 5 years: stood at $153999.3 in 2021, then declined by 5.19% to $145999.4 in 2022, then gained by 6.56% to $155574.9 in 2023, then increased by 24.74% to $194058.7 in 2024, then surged by 110.18% to $407881.4 in 2025.
- Per Business Quant, the three latest ACIU Amortizatization of Intangibles figures stand at $407881.4 (Q4 2025), $341279.9 (Q3 2025), and $314051.5 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 407,881.35 |
| Dec 31, 2025 | 407,881.35 |
| Sep 30, 2025 | 341,279.90 |
| Sep 30, 2025 | 341,279.90 |
| Jun 30, 2025 | 314,051.46 |
| Jun 30, 2025 | 314,051.46 |
| Mar 31, 2025 | 279,174.88 |
| Mar 31, 2025 | 279,174.88 |
| Dec 31, 2024 | 194,058.71 |
| Dec 31, 2024 | 194,058.71 |
| Sep 30, 2024 | 196,215.23 |
| Sep 30, 2024 | 196,215.23 |
| Jun 30, 2024 | 187,984.89 |
| Jun 30, 2024 | 187,984.89 |
| Mar 31, 2024 | 191,328.95 |
| Mar 31, 2024 | 191,328.95 |
| Dec 31, 2023 | 155,574.92 |
| Dec 31, 2023 | 155,574.92 |
| Sep 30, 2023 | 153,972.75 |
| Sep 30, 2023 | 153,972.75 |
| Jun 30, 2023 | 150,143.70 |
| Jun 30, 2023 | 150,143.70 |
| Mar 31, 2023 | 144,875.79 |
| Mar 31, 2023 | 144,875.79 |
| Sep 30, 2022 | 145,999.39 |
| Sep 30, 2022 | 145,999.39 |
| Jun 30, 2022 | 147,437.61 |
| Jun 30, 2022 | 147,437.61 |
| Mar 31, 2022 | 151,593.17 |
| Mar 31, 2022 | 151,593.17 |
| Dec 31, 2021 | 153,999.30 |
| Dec 31, 2021 | 153,999.30 |
| Sep 30, 2021 | 154,656.33 |
| Sep 30, 2021 | 154,656.33 |
| Jun 30, 2021 | 129,404.36 |
| Jun 30, 2021 | 129,404.36 |
| Mar 31, 2021 | 118,348.32 |
| Mar 31, 2021 | 118,348.32 |
| Dec 31, 2020 | 120,570.96 |
| Dec 31, 2020 | 120,570.96 |
| Sep 30, 2020 | 117,327.47 |
| Sep 30, 2020 | 117,327.47 |
| Jun 30, 2020 | 111,045.87 |
| Jun 30, 2020 | 111,045.87 |
| Mar 31, 2020 | 111,655.43 |
| Mar 31, 2020 | 111,655.43 |
| Dec 31, 2019 | 109,121.43 |
| Dec 31, 2019 | 109,121.43 |
| Sep 30, 2019 | 106,569.89 |
| Sep 30, 2019 | 106,569.89 |
| Jun 30, 2019 | 103,720.02 |
| Jun 30, 2019 | 103,720.02 |
| Mar 31, 2019 | 103,418.44 |
| Mar 31, 2019 | 103,418.44 |